[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353459-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353459-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bias-in-meta-analytic-modeling-of-surrogate-endpoints-in-cancer-screening-trials-research-article","Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials - Research Article","","Meta-analytic modeling estimates the functional relationship between a primary and a surrogate endpoint using summary data from completed clinical trials. Parameters are used to judge surrogate quality, including whether late-stage cancer incidence can stand in for cancer mortality in screening settings. A key problem is that uncertainty in trial-level estimates can distort surrogacy assessment because trials report estimates rather than true parameters. This study shows by simulation and theory that such uncertainty can bias results toward apparent positive surrogate performance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bias-in-meta-analytic-modeling-of-surrogate-endpoints-in-cancer-screening-trials-research-article/353459/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bias-in-meta-analytic-modeling-of-surrogate-endpoints-in-cancer-screening-trials-research-article/353459.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of meta-analytic modeling in surrogate endpoint assessment?","Question",{"text":63,"@type":64},"It estimates the functional relationship between a primary endpoint and a surrogate endpoint using summary data from completed clinical trials, and then uses model parameters to evaluate the surrogate’s quality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why can trial-level estimate uncertainty bias surrogate evaluation?",{"text":68,"@type":64},"Because each trial provides estimated primary and surrogate endpoints rather than their true parameter values, uncertainty in trial-level estimates can distort how surrogacy is judged in the meta-analytic model.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study focus on for cancer screening trials?",{"text":72,"@type":64},"It examines cancer screening trials using late-stage cancer incidence as the surrogate, and reassesses correlations between primary and surrogate endpoints in ovarian cancer screening trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353459,1790617357,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Statistics in Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nBias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials  \nJames P. Long1  | Abhishikta Roy2 | Ehsan Irajizad1 | Kim-Anh Do1 | Yu Shen1  \n1University of Texas MD Anderson Cancer Center, Houston, Texas, USA | 2University of Texas School of Public Health, Houston, Texas, USA Correspondence: Yu Shen ([yshen@mdanderson.org](yshen@mdanderson.org))  \nReceived: 6 August 2025 | Revised: 12 March 2026 | Accepted: 21 August 2026  \nABSTRACT  \nIn meta-analytic modeling, the functional relationship between a primary and surrogate endpoint is estimated using summary data from a set of completed clinical trials. Parameters in the meta-analytic model are used to assess the quality of the proposed surrogate. Recently, meta-analytic models have been employed to evaluate whether late-stage cancer incidence can serve as a surrogate for cancer mortality in cancer screening trials. A major challenge in meta-analytic models is that uncertainty of trial-level estimates affects the evaluation of surrogacy, since each trial provides only estimates of the primary and surrogate endpoints rather than their true parameter values. In this work, we show via simulation and theory that trial-level estimate uncertainty may bias the results of meta-analytic models toward positive findings ofthe quality of the surrogate. We focus on cancer screening trials and the late-stage incidence surrogate. We reassess correlations between primary and surrogate endpoints in Ovarian cancer screening trials. Our findings indicate that completed trials provide limited information regarding quality of the late-stage incidence surrogate. These results support restricting meta-analytic regression usage to settings where trial-level estimate uncertainty is incorporated into the model.  \n1 | Introduction  \nCancer screening aims to reduce mortality by detecting tumorsat an early stage, when treatments are more likely to be effective. Screening programs have been widely used in clinical practice including mammograms for breast cancer, sigmoidoscopy for colorectal cancer, and low-dose computed tomography (LDCT) scans for lung cancer in smokers [1]. New imaging and molecular diagnostic technologies have led to the development of promising new screening techniques, which are at various stages of scientific and commercial development [2–4] .  \nBefore beingwidely adopted, a screening method should be tested in clinical trials to demonstrate benefit to people at average or increased risk of the cancer. These trials typically randomize subjects to two arms: a standard of care (control) arm and a screening  \n(intervention) arm. Cancer-specific mortality is often considered the gold-standard primary endpoint in screening trials [5, 6] .  \nUnfortunately, using reduction in cancer-specific mortality to demonstrate efficacy is costly, both in length of follow-up time and trial sample size. For example, the National Lung Screening Trial (NLST) demonstrated a 20.0% decrease in lung cancer-specific mortality in the screen arm (annual LDCT) compared with the control arm (annual chest radiography) [7] . The trial enrolled over 50,000 healthy subjects with more than 7 years of follow-up. In another example, the Health Insurance Plan (HIP) mammography trial enrolled 62,000 women with 18 years of follow-up [8] .  \nSurrogate (also known as alternative) endpoints, which can be determined at the time of cancer diagnosis (e.g., tumor stage  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Statistics in Medicine published by John Wiley & Sons Ltd.  \nStatistics in Medicine, 2026; 45:e70731 1 of 11  \n[https://doi.org/10.1002/sim.70731](https://doi.org/10.1002/sim.70731)  \nor size), may facilitate faster evaluation of efficacy than mortality endpoints. Amon","cbCainCMCdtBisbs","https://ap.wps.com/l/cbCainCMCdtBisbs","pdf",854816,11,"English","# Introduction\n## Cancer screening endpoints and trial design\n## Surrogate endpoints and late-stage incidence\n## Why surrogate validity is uncertain","[{\"question\":\"What is the main goal of meta-analytic modeling in surrogate endpoint assessment?\",\"answer\":\"It estimates the functional relationship between a primary endpoint and a surrogate endpoint using summary data from completed clinical trials, and then uses model parameters to evaluate the surrogate’s quality.\"},{\"question\":\"Why can trial-level estimate uncertainty bias surrogate evaluation?\",\"answer\":\"Because each trial provides estimated primary and surrogate endpoints rather than their true parameter values, uncertainty in trial-level estimates can distort how surrogacy is judged in the meta-analytic model.\"},{\"question\":\"What does the study focus on for cancer screening trials?\",\"answer\":\"It examines cancer screening trials using late-stage cancer incidence as the surrogate, and reassesses correlations between primary and surrogate endpoints in ovarian cancer screening trials.\"}]","Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials - Research Article | PDF",1790105519,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d1e12d128ac216a92abeed461be90e6.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5636a7a8a11d9634270d6fcc05065515.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adbd524b810e8d9cc2af7c911019b940.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae9db345062954d108d00739b3c30e4d.webp",980,1287]